Bayer today presented the results from the global, pivotal Phase III OCEANIC-STROKE study evaluating the use of its ...

A new predictive tool may help identify patients at risk for poststroke dementia, potentially accelerating research and ...

Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and ...

The factor XIa inhibitor asundexian reduced recurrent ischemic stroke without increasing major or minor bleeding in patients ...

In a U.S. ED observation TIA cohort, transthoracic echocardiography identified high risk cardioembolic features in nearly 1 in 5, most often patent foramen ovale and reduced LVEF.

An investigational anti-clotting medication, asundexian, has demonstrated a reduction in the risk of a second ischemic ...

The rationale behind the treatment is that, because genetic FXI deficiency has been linked with reduced risk of ischemic ...

An investigational anti-clotting medication, asundexian, demonstrated a reduction in the risk of a second ischemic ...

For patients with noncardioembolic ischemic stroke or high-risk transient ischemic attack, asundexian, a factor XIa inhibitor, reduced risk for secondary stroke with no excess risk for any bleeding vs ...

Bayer presents positive data on asundexian, which shows superior efficacy with no added bleeding risk, boosting hopes for regulatory approval.

A new risk calculator accurately estimated the likelihood of adults developing dementia within ten years after a stroke, ...

For Medicare beneficiaries aged 65 years and older, there is no evidence of elevated stroke risk immediately after vaccination with either brand of the COVID-19 bivalent vaccine, according to a study ...